leisure time -WSS

leisure time

author：leisure time 2025-08-23 06:47:11 - browse：43

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Researchers explore possible ties between long Covid, menopause

hotspot

WSS

First Opinion Podcast: Long Covid needs a new approach

Beam Therapeutics to lay off 20% of its staff, re

Today's health inequities arise from racist U.S. history, say experts

Publishing genetic code of viruses could cause disaster

STAT Summit: Michael J. Fox on progress in Parkinson's research

NIH confirmation hearing shows politicization of research

focus

leisure time

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

How climate

Affirmative action in medical school literally saved lives

The explosion of genetic testing requires a new approach

In Memoriam: Notable people who died in 2023

Weight loss drugs should be covered by insurers, AMA says

DIEP, the 'gold standard' of breast reconstruction, is under threat

CVS, Rite Aid closures threaten to worsen pharmacy deserts

Walensky prepares to leave CDC — and Congress — behind

STAT Readout Newsletter: Today's biggest biotech updates

hotspot

White House drug czar issues call for 'recovery

Study suggests Covid rebound is far more common with Paxlovid than without

STAT Summit: How a Chicago ER doctor tackles gun violence

STAT Summit: GSK CEO on pharma giant's new direction

Ventyx halts psoriasis drug development after lackluster trial results

CVS, Rite Aid closures threaten to worsen pharmacy deserts

leisure time

hotspot

focus

focus